NX-5948

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
572 patients (estimated)
Sponsors
Nurix Therapeutics, Inc.
Tags
Bruton's Tyrosine Kinase (BTK) Degrader
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1374
NCT Identifier
NCT05131022

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.